49 results about "Adenocarcinoma prostate" patented technology

Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and/or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacterium and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn's Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hemodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma, Dermatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocytopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave's Disease, Hypothyreoidism, Type 1 Diabetes Mellitus, Addison's Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications, Cataracts, Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations, Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus)), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms, and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig's and Alzheimer's Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.

Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.

Compositions and methods for diagnosing, monitoring, or treating cancers. Genes encoding transmembrane proteins that are over-expressed in colon, lung, breast, prostate, liver, stomach, esophagus, or kidney cancer tissues are identified. These transmembrane genes can be used as biological markers for the detection or diagnosis of cancers. These genes can also serve as targets for cancer therapeutics. In addition, these genes can also be used for screening for anti-cancer drugs.

The invention relates to a maackia amurensis total flavone extract as well as a preparation method and an application thereof. The maackia amurensis total flavone extract is prepared through the method which comprises the following steps: extracting the heartwood, velamen, bark, twig bark, leaves, stalks, flowers, fruits and seeds of maackia amurensis by utilizing an extraction solvent; filtering and concentrating the extracting solution; passing the concentrated solution through the macroporous adsorption resin, and eluting by utilizing methanol or ethanol water of different concentrations; and collecting and concentrating the eluant until the solution is dry, so that the maackia amurensis total flavone extract is obtained. The maackia amurensis total flavone extract which is obtained through the method contains the total flavone content of 15%- 90%, tectoridin of 1-15% and SaikoisoflavonosideA of 6-57%. The maackia amurensis total flavone extract has an estrogen effect, can be used for preparing estrogen drugs or health-care food and is used for preventing or treating breast cancer, prostate cancer, colon cancer, osteoporosis and climacteric syndrome.

This invention is directed to potent inhibitors of protein tyrosine kinase alone or in synergistic combination with antiangiogenic or chemotherapeutic agents for the abrogation of mature vasculature within chemotherapeutic refractory tumors, pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cell proliferation, and particularly treatment of brain cancer, ovarian cancer, pancreatic cancer prostate cancer, and human leukemias, such as CML, AML or ALL.

The invention relates generally to the changes in gene expression in human tissues from cancer patients. The invention relates specifically to human gene families which are differentially expressed in cancer tissues of breast, colon, esophagus, kidney, liver, lung, lymph node, ovary, pancreas, prostate, rectum, and/or stomach compared to corresponding normal tissues.

The present invention relates to a method for the improved treatment of a cancerous disease in a patient and/or for the palliation of pain associated with cancer diseases, comprising the administration of a tubulin interacting compound in combination with a bone-localising radiopharmaceutical to said patient in an effective amount that will not cause any substantial ablation of the bone marrow of said patent. In particular, the cancerous disease is selected from the group of cancer diseases, comprising multiple myeloma, leukaemia, lymphoma, breast cancer, prostate cancer, gynecologic cancer, gastric cancer ovarian cancer, lung cancer and/or renal cell carcinoma. In a preferred embodiment, the bone-localising radiopharmaceutical is samarium Sm 153 lexidronam and the tubulin interacting compound is docetaxel.

The invention discloses a 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazoline-4(3H)-one compound,a preparation method and applications thereof, wherein the structural general formula (I) of the compoundis defined in the specification, R1 is hydrogen atom, morpholinomethyl, piperazinomethyl or substituted piperazinomethyl, R2 is hydrogen atom, butyl, morpholine substituted alkyl, benzyl, substitutedbenzyl, tryptamine, substituted tryptamine or N,N-dimethylamino, R3 is-C(O)R4 or-SO2R5, R4 and R5 are alkyl (C3-C6 alkyl), cycloalkyl (3-6-membered ring), alkoxy or alkyl substituted amino, and n is 1, 2, 3 or 4. The compound of the invention has inhibition activity on breast cancer, prostate cancer and human neuroblastoma.

A system for expression-based discrimination of distinct clinical disease states in prostate cancer is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated with recurrent or non-recurrent prostate cancer. The Prostate Cancer Prognostic system provides for sets of “prostate cancer prognostic” target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying prostate cancer tissue.

The invention discloses a non-natural amino acid short peptide and application thereof in tumor resistance. The amino acid sequence of the non-natural amino acid short peptide is shown as {D-Tyr(Me)}-Asp-Dpr-Asn-{D-Glu}-Thr-Cha. The non-natural amino acid oligopeptide can be synthesized by adopting an existing conventional method. The short peptide can inhibit proliferation and migration of tumor cells, achieves an anti-tumor effect, and does not harm the activity of normal cells. Therefore, the non-natural amino acid short peptide can be used for preparing antitumor drugs for treating esophageal cancer, lung cancer, liver cancer, breast cancer, prostate cancer, gastric cancer, colorectal cancer and other malignant tumors.

The invention discloses a 18beta-glycyrrhetinic acid carbamate derivative, which has a structure shown as formula (I) or (II) in the specification. The compound provided by the invention has a brand new structure, and has significant inhibitory effect on lung cancer, liver cancer, colon cancer, breast cancer and prostate cancer cell lines. And the antitumor activity of parts of the compounds is close to crizotinib.

The present invention provides convergent processes for preparing (−)-beta-elemene, (−)-beta-elemenal, (−)-beta-elemenol, and (−)-beta-elemene fluoride and analogues thereof. Also provided are intermediates useful for preparing (−)-beta-elemene. The present invention further provides novel compositions based on analogues of (−)-beta-elemene, (−)-beta-elemenal, (−)-beta-elemenol, (−)-beta-elemene fluoride and methods for the treatment of cancer, such as brain tumor, lung cancer, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric intestional cancer, and stomach cancer. The inventors propose a combination therapy using 1) one or more of the following anti-cancer agents: including, but not limited to, Cisplatin, 5-FU, Taxol, Taxol derivatives, and any anti-cancer agent, and 2) one or more of the following (−)-beta-elemene and its analogs, including (−)-beta-elemene, (−)-beta-elemenal, (−)-beta-elemenol, (−)-beta-elemene fluoride, and their analogs, and (−)-beta-elemene's intermediate in its chemical synthesis, for the treatment of cancer, especially for the treatment of brain tumor, lung cancer, ovarian cancer, bladder cancer, cervical cancer, colon cancer, breast cancer, and prostate cancer.

The invention belongs to the field of drug synthesis, and relates to a pyridine-containing BODIPY compound represented by a general formula (I), and a quaternary ammonium salt thereof, particularly toa pyridine quaternary ammonium salt photosensitizer, a preparation method and medical applications thereof. According to the invention, the results of in-vitro photosensitization efficiency and tumorcell inhibition activity tests show that the compound has good antineoplastic activity, can be further used for preparing new antineoplastic drugs, and is used for treating non-specific wide tumors such as gastric cancer, breast cancer, prostate cancer, lung cancer, colon cancer, bladder cancer, ovarian cancer, skin cancer and cervical cancer.

The invention discloses a medicine composition applied to chemotherapy of tumors, and particularly discloses application of sildenafil serving as an antitumor medicine sensitizer to preparation of chemotherapy medicines for tumors. According to the invention, sildenafil is used as the sensitizer, and sildenafil is combined with anti-tumor drugs such as oxaliplatin, irinotecan or capecitabine through a carrier to prepare the anti-tumor composition which can be used for effectively killing tumor cells such as colorectal cancer or drug-resistant tumor cells. According to the application, the sensitization effect of sildenafil on antitumor drugs is verified at a cellular level for the first time, the treatment synergistic effect of sildenafil serving as the sensitizer in cancers such as colorectal cancer, gastric cancer, liver cancer, breast cancer and prostatic cancer is verified, and a new way and means are provided for effectively treating tumors.

The invention discloses a health cake capable of clearing heat and removing internal heat and a preparation method of the health cake. The health cake comprises the raw materials of 200-220 parts of low-gluten flour, 100-160 parts of black bean powder, 10-15 parts of loquat fruits, 1-5 parts of white sugar, 10-20 parts of coix seed powder, 8-12 parts of dandelions, 2-4 parts of green tea powder, 4-10 parts of honey, 4-6 parts of eggs, 2-3 parts of smoked plums, 2-4 parts of lily powder, 8-10 parts of osmanthus fragrans and 1-3 parts of butter. The cake is rich in raw materials and easy to absorb, and has the effects of clearing away heat and internal heat, delaying senescence, promoting fat metabolism and reducing harm of trans-fatty acid to a human body; the added green tea powder has good anti-oxidation and calming effects and can relieve fatigue; the black bean powder has the effects of resisting oxidation and delaying aging, and black beans are rich in isoflavone and anthocyanin; isoflavone is a plant estrogen, can effectively inhibit breast cancer, prostate cancer and colon cancer, and is also very helpful for preventing and treating osteoporosis of middle-aged and elderly people; anthocyanin is a good antioxidant source and has a better antioxidant effect in an acidic environment; and the health cake is simple in structure, convenient to operate and worthy of popularization.

The invention discloses a probe composition. According to the composition, through meta analysis of methylation data of a TCGA database and a GEO database, a 6.5 Kbp capture region is screened out, and the 6.5 Kbp capture region comprises up to 66 methylation change genes highly related to cancer and a non-coding DNA region. The method can be used for detecting methylation level changes of 11 common cancers such as esophageal cancer, gastric cancer, colorectal cancer, lung cancer, liver cancer, pancreatic cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer and endometrial cancer at one time. The probe composition can be used for early screening of asymptomatic people and prognosis detection of cancer patients, and the breadth of detection genes of the probe composition is superior to that of detection genes in the prior art and products.

The invention discloses an inhibitor for knocking down circXPO1 and application of the inhibitor in preparation of a medicine for treating glioma. At present, the research reports that the expression of circXPO1 is related to osteosarcoma, lung adenocarcinoma and prostate cancer, and the related effect of circXPO1 on malignant glioma is not reported. According to the invention, a pair of shRNAs is designed according to the splicing site of circXPO1, and the shRNAs can significantly inhibit the expression level of circXPO1 and can inhibit the activity, proliferation and migration of glioma.

The invention discloses a novel butoxyphenyl-methanesulfonamide compound with formula I for regulating the activity of estrogen-related receptors, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salt can be used for the preparation of estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.